2026-10-18T23:53:45Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/requestoai:ebyu-rdlopen.rawdatalibrary.net:ebyu/128962026-10-18T21:13:24Zopenairedrivercom_ebyu_10000col_ebyu_10001Design of Besifloxacin HCl-Loaded Nanostructured Lipid Carriers: In Vitro and Ex Vivo EvaluationPolat, Heybet KeremKurt, NihatAytekin, ErenAkdaǧ Çayll, YagmurBozdaǧ Pehlivan, SibelCalis, Semabesifloxacincyclodextrinnano drug deliverynanostructured lipid carriersocularAzepinesChitosanDrug CarriersFluoroquinolonesHumansKeratitisLipidsNanostructuresParticle Sizebeta cyclodextrin sulfobutyl etherlipidnanocarrierazepine derivativedrug carriernanomaterialquinolone derivativeanimal tissueantibiotic resistanceARPE-19 cell lineArticlecontrolled studydrug delivery systemdrug formulationdrug penetrationdrug releaseObjective: In the treatment of severe cases of bacterial keratitis, conventional eye drops containing antibiotics should be applied daily and very frequently. The aim of this study is to develop low-dose high-effect formulations with the prepared nanostructured lipid carrier (NLC) formulations to reduce antibiotic resistance and increase patient compliance. Methods: NLC formulations were loaded with besifloxacin HCl (BHL) and the besifloxacin HCl: sulfobutyl ether beta-cyclodextrin (SBE-CD) complex. Positive charge was gained with chitosan, and corneal permeation and resolubility were increased with SBE-CD. In vitro characterization studies, permeability studies, and cytotoxicity and ex vivo transport studies were carried out. Results: In this study, it was found that SBE-CD increased BHL's solubility by 8-fold based on phase solubility studies. The optimized NLCs were small in size (13.63-16.09 nm) with a low polydispersity index (0.107-0.181) and adequate BHL drug loading efficiency. In vitro release studies showed that formulations were released approximately for 8 h and at levels over the minimum inhibitory concentration of Pseudomonas aeruginosa and Staphylococcus aureus. NLC formulations had a better corneal permeation rate than the marketed product during 6 h of ex vivo studies. Conclusions: According to in vitro and ex vivo data, it was determined that the most favorable NLC formulation was the formulation containing BHL/SBE-CD that was covered with chitosan. It has the highest drug loading capacity and one of the highest ex vivo corneal passage levels, along with desired drug release. The formulation containing BHL/SBE-CD and chitosan can be a potential alternative for the treatment of bacterial keratitis. © Copyright 2022, Mary Ann Liebert, Inc.Mary Ann Liebert Inc.2022Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/12896https://doi.org/10.1089/jop.2022.00081080-7683enJournal of Ocular Pharmacology and Therapeuticsinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/12896